LM-302 Injection

DRUG2 trials

Sponsors

LaNova Medicines Zhejiang Co., Ltd., Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Conditions

AdenocarcinomaAdvanced Solid Tumor

Phase 1

Study of LM-302 in Patients With Advance Solid Tumors

CompletedNCT05161390

LaNova Medicines Zhejiang Co., Ltd.Advanced Solid Tumor

Start: 2021-11-26End: 2025-01-10Updated: 2025-09-12

Phase 3

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Not yet recruitingNCT07385703

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Adenocarcinoma

Start: 2026-03-01End: 2030-05-01Target: 752Updated: 2026-02-04

Related Papers

A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.

Journal of Clinical Oncology2024-06-0111 citations